Bright Science. Clear Results.
NanoDetection Technology™'s universal detection system brings speed, accuracy, and scalability to infectious disease testing.
Who We Are
NanoDetection Technology™ (NDT) is a Delaware C corporation established to commercialize an advanced diagnostic instrument utilizing microchip technology for challenging human and veterinary infectious disease applications. The patented NDT “Biochip” features 25 discrete diodes for the rapid detection of multiple biomarkers, a key component of the NDT biosensor platform, which offers significant advantages over traditional detector technologies used in current diagnostic instruments.
Our Vision
To integrate advances in engineering, biology, and chemistry to deliver next-generation diagnostic solutions that address critical challenges in both human and veterinary medicine.
Our Board of Directors
-
Doug Durand - Chief Executive Officer
Doug Durand is the founder and managing director of Durand Venture Associates, LLC, the largest shareholder in NDT. He has been a member of the board since 2008 and served on the board of Healthspex, before it became NanoDetection in 2008. He brings 26 years of pharmaceutical sales and marketing experience. He is a former VP of sales at ePocrates Inc., executive director of marketing at AstraZeneca/Astra Pharmaceuticals, VP of sales, TAP Pharmaceuticals, and Director of Marketing and Regional Sales Director at Merck. He is a registered pharmacist and a University of Rhode Island graduate.
-
Samuel Lee - Board Director
Dr. Samuel Lee joined our Board of Directors in 2018. He brings a multidisciplinary convergence of experience in the life sciences, physical sciences, and computer sciences to successfully develop breakthroughs in healthcare. Dr. Lee is currently the co-founder and President at Eikonoklastes Therapeutics. Prior to Eikonoklastes, Sam was a Director at CincyTech, where he led a number of successful investments and actively supported operations in early-stage biotech and medical device companies
Dr. Lee completed his medical training at the University of Cincinnati, formal business and public health education at the Stanford Graduate School of Business and Johns Hopkins, and post-graduate research fellowship at Northwestern University and Cincinnati Children’s Hospital Medical Center.
-
Edward Smith - Board Director
Ed Smith joined our Board of Directors in 2025. A seasoned healthcare executive, he has held senior leadership roles at organizations from start-ups to Fortune 100 companies across diagnostics, pharmaceuticals, biotech, and health systems. Known for blending commercial acumen with clinical expertise, he has led financial improvements across health systems, created competitive advantage through multi-party alliances, opened new markets for innovative products, and managed complex commercial operations.
Ed is a registered pharmacist and a Purdue University graduate. He holds an MBA from Indiana University Kelley School of Business and is a Board Certified Medical Affairs Specialist.
